Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]
It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]
^Liu D, Mamorska-Dyga A (July 2017). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi:10.1186/s13045-017-0512-1. PMC 5534090. PMID 28754125.
^Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. (December 2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–48. doi:10.1124/jpet.114.218164. PMID 25253883.
Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against...
inhibitor for prevention of thrombosis; approved by FDA in June 2017. Cerdulatinib, an investigational - not approved - oral multikinase SYK/JAK inhibitor...
activity relationship of may be found in the article on JAK3 inhibitors. Cerdulatinib (PRT062070) dual SYK/JAK inhibitor for hematological malignancies. Gandotinib...